CN115397447A - 用于治疗葡萄球菌感染的噬菌体组合物 - Google Patents

用于治疗葡萄球菌感染的噬菌体组合物 Download PDF

Info

Publication number
CN115397447A
CN115397447A CN202180021063.3A CN202180021063A CN115397447A CN 115397447 A CN115397447 A CN 115397447A CN 202180021063 A CN202180021063 A CN 202180021063A CN 115397447 A CN115397447 A CN 115397447A
Authority
CN
China
Prior art keywords
phage
seq
polynucleotide sequence
subject
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180021063.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·L·科拉
B·C·瓦纳姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amata Pharmaceutical
Original Assignee
Amata Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amata Pharmaceutical filed Critical Amata Pharmaceutical
Publication of CN115397447A publication Critical patent/CN115397447A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180021063.3A 2020-02-18 2021-02-18 用于治疗葡萄球菌感染的噬菌体组合物 Pending CN115397447A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062978006P 2020-02-18 2020-02-18
US62/978,006 2020-02-18
PCT/US2021/018623 WO2021168147A1 (en) 2020-02-18 2021-02-18 Bacteriophage compositions for treating staphylococcus infection

Publications (1)

Publication Number Publication Date
CN115397447A true CN115397447A (zh) 2022-11-25

Family

ID=77272316

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180021063.3A Pending CN115397447A (zh) 2020-02-18 2021-02-18 用于治疗葡萄球菌感染的噬菌体组合物

Country Status (8)

Country Link
US (4) US20210252083A1 (https=)
EP (1) EP4106782A4 (https=)
JP (1) JP2023513934A (https=)
CN (1) CN115397447A (https=)
AU (1) AU2021224912A1 (https=)
CA (1) CA3171467A1 (https=)
IL (1) IL295408A (https=)
WO (1) WO2021168147A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259170A1 (en) * 1999-04-27 2004-12-23 Sokoloff Alexander V. Process for utilizing epitopes recognized by natural antibodies
CN110545670A (zh) * 2017-03-08 2019-12-06 飞瑞赛德斯制药公司 噬菌体疗法
CN110719784A (zh) * 2017-02-13 2020-01-21 阿玛塔制药公司 治疗性噬菌体组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214773B2 (en) * 2015-09-24 2022-01-04 San Diego State University (Sdsu) Foundation Antibacterial and protective bacteriophage formulations and methods for making and using them
CN112218659A (zh) * 2018-01-02 2021-01-12 阿玛塔制药股份有限公司 用于治疗葡萄球菌感染的治疗性噬菌体组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259170A1 (en) * 1999-04-27 2004-12-23 Sokoloff Alexander V. Process for utilizing epitopes recognized by natural antibodies
CN110719784A (zh) * 2017-02-13 2020-01-21 阿玛塔制药公司 治疗性噬菌体组合物
CN110545670A (zh) * 2017-03-08 2019-12-06 飞瑞赛德斯制药公司 噬菌体疗法
US20200030392A1 (en) * 2017-03-08 2020-01-30 Pherecydes Pharma Phage therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VANDERSTEEGEN, K. 等: "Staphylococcus phage vB_SauM_Remus, complete genome", 《GENBANK DATABASE》, 9 May 2019 (2019-05-09), pages 022090 *
李萍 等: "耐甲氧西林金黄色葡萄球菌鉴定及噬菌体分型", 《中华医院感染学杂志》, 31 December 1994 (1994-12-31), pages 184 - 185 *

Also Published As

Publication number Publication date
IL295408A (en) 2022-10-01
EP4106782A1 (en) 2022-12-28
WO2021168147A1 (en) 2021-08-26
US20240189373A1 (en) 2024-06-13
AU2021224912A1 (en) 2022-09-01
US20230092021A1 (en) 2023-03-23
US20260041723A1 (en) 2026-02-12
JP2023513934A (ja) 2023-04-04
US20210252083A1 (en) 2021-08-19
CA3171467A1 (en) 2021-08-26
EP4106782A4 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
RU2725726C2 (ru) Бактериофаги, фаговые пептиды и способы их применения
DK3209381T3 (en) COMPOSITIONS COMPREHENSIVE BAKERY STUES
CN108359643B (zh) 新型金黄色葡萄球菌噬菌体及其组合物和应用
AU2017353868C1 (en) Synthetic chimeric poxviruses
CN114107220B (zh) 噬菌体疗法
KR102360880B1 (ko) 황색포도상구균 유래 점보박테리오파지 PALS2의 엔도라이신 LysPALS21
AU2025203392A1 (en) Therapeutic bacteriophage compositions
KR20220024508A (ko) 생물학적으로 봉쇄된 박테리아 및 그의 용도
CN112243377A (zh) 用于治疗和预防细菌相关的癌症的噬菌体
KR20220148823A (ko) 천연 또는 합성 dna에 의해 생산된 폭스바이러스-기반 벡터 및 그의 용도
KR20240021274A (ko) 반코마이신 내성 장구균에 대한 박테리오파지
AU2018256922B2 (en) Targeted gene disruption methods and immunogenic compositions
KR101993123B1 (ko) 신규한 병원성 대장균 특이 박테리오파지 eco5 및 이를 포함하는 항균 조성물
CN112261951A (zh) 包含合成嵌合痘苗病毒的干细胞及其使用方法
CN115397447A (zh) 用于治疗葡萄球菌感染的噬菌体组合物
HK40083362A (en) Bacteriophage compositions for treating staphylococcus infection
CN114410591B (zh) 一种耐酸耐高温的金黄色葡萄球菌噬菌体及其组合物、试剂盒及其应用
JP2001292771A (ja) アブラムシ共生バクテリアのゲノムｄｎａ
KR20230112860A (ko) 스타필로코커스균 특이 박테리오파지 kmsp1 및 이를 포함하는 항균 조성물
HK40042130A (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
HK40042802A (en) Bacteriophage for treatment and prevention of bacteria-associated cancers
KR20130142820A (ko) 스태필로코커스 아우레우스의 박테리오파아지 및 그 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40083362

Country of ref document: HK